Tag: HighTide Therapeutics Inc.
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2...
Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)
HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the...
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at...
HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic...
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the...
HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic...
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study...
HighTide Therapeutics Inc. (HighTide), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the...
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance...
Global biopharmaceutical company focusing on metabolic and digestive diseasesProceeds to fund clinical and business development
HighTide Therapeutics Inc. (HighTide),...
